ARCHIVES

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

Without Advisor’s Input, Healy Approves Protocol For Gene Therapy

January 15, 1993

In Brief: Curt Appointment Now Official; Bipartisan Effort Seeks $150 Million FDA Budget Increase

April 21, 1989

DCT Advisors Approve Recompetition Of Drug Discovery Groups

June 23, 1995

BMS Demands Resignation Of Two ImClone Executives

February 8, 2002

NCI Will Encourage More Activity In Environment Carcinogenesis

June 21, 1974

Cetuximab Plus Irinotecan Increases PFS In Metastatic Colorectal Cancer, EPIC Finds

April 27, 2007